The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).
 
Peter R. Galle
No Relationships to Disclose
 
Richard S. Finn
No Relationships to Disclose
 
Shukui Qin
No Relationships to Disclose
 
Masafumi Ikeda
No Relationships to Disclose
 
Andrew X. Zhu
No Relationships to Disclose
 
Tae-You Kim
No Relationships to Disclose
 
Masatoshi Kudo
No Relationships to Disclose
 
Valeriy Vladimirovich Breder
No Relationships to Disclose
 
Philippe Merle
No Relationships to Disclose
 
Ahmed Omar Kaseb
No Relationships to Disclose
 
Daneng Li
No Relationships to Disclose
 
Sohail Mulla
No Relationships to Disclose
 
Wendy Verret
No Relationships to Disclose
 
Derek-Zhen Xu
No Relationships to Disclose
 
Sairy Hernandez
No Relationships to Disclose
 
Juan Liu
No Relationships to Disclose
 
Chen Huang
No Relationships to Disclose
 
Ho Yeong Lim
No Relationships to Disclose
 
Ann-Lii Cheng
No Relationships to Disclose
 
Michel Ducreux
No Relationships to Disclose